Lorlatinib in Frontline Therapy for ALK+ Advanced Non-Small-Cell Lung Cancer: Still a Matter of Debate? Perol M, Swalduz A. J Clin Oncol 2022 Jun 9:JCO2200859. doi: 10.1200/JCO.22.00859.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Perol M, Swalduz A. Lorlatinib in Frontline Therapy for ALK+ Advanced Non-Small-Cell Lung Cancer: Still a Matter of Debate? J Clin Oncol 2022 Jun 9:JCO2200859. doi: 10.1200/JCO.22.00859.
PMID: 35679525